Dark Canyon Labs is pleased to announce the completion of a multicenter, randomized, investigator blinded, non-inferiority Phase 2 Clinical Trial. DCL-101, a novel Pill Prep, was compared to standard split-dose GoLYTELY® in adult outpatients undergoing routine colonoscopy.
Based on tolerability, safety, and efficacy results, Dark Canyon Labs is excited to announce that DCL-101 will move ahead for further evaluation in two definitive Phase 3 trials.
Watch for additional details soon. For more information, contact email@example.com